These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 28400167)
1. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167 [TBL] [Abstract][Full Text] [Related]
2. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118 [TBL] [Abstract][Full Text] [Related]
3. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959 [TBL] [Abstract][Full Text] [Related]
4. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945 [TBL] [Abstract][Full Text] [Related]
5. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180 [TBL] [Abstract][Full Text] [Related]
6. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811 [TBL] [Abstract][Full Text] [Related]
7. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664 [TBL] [Abstract][Full Text] [Related]
8. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658 [TBL] [Abstract][Full Text] [Related]
9. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869 [TBL] [Abstract][Full Text] [Related]
11. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753 [TBL] [Abstract][Full Text] [Related]
12. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274 [TBL] [Abstract][Full Text] [Related]
13. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. Karnes RJ; Bergstralh EJ; Davicioni E; Ghadessi M; Buerki C; Mitra AP; Crisan A; Erho N; Vergara IA; Lam LL; Carlson R; Thompson DJ; Haddad Z; Zimmermann B; Sierocinski T; Triche TJ; Kollmeyer T; Ballman KV; Black PC; Klee GG; Jenkins RB J Urol; 2013 Dec; 190(6):2047-53. PubMed ID: 23770138 [TBL] [Abstract][Full Text] [Related]
14. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305 [TBL] [Abstract][Full Text] [Related]
15. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. Glass AG; Leo MC; Haddad Z; Yousefi K; du Plessis M; Chen C; Choeurng V; Abdollah F; Robbins B; Ra S; Richert-Boe KE; Buerki C; Pearson K; Davicioni E; Weinmann S J Urol; 2016 Jun; 195(6):1748-53. PubMed ID: 26626216 [TBL] [Abstract][Full Text] [Related]
16. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Tosoian JJ; Birer SR; Jeffrey Karnes R; Zhang J; Davicioni E; Klein EE; Freedland SJ; Weinmann S; Trock BJ; Dess RT; Zhao SG; Jackson WC; Yamoah K; Dal Pra A; Mahal BA; Morgan TM; Mehra R; Kaffenberger S; Salami SS; Kane C; Pollack A; Den RB; Berlin A; Schaeffer EM; Nguyen PL; Feng FY; Spratt DE Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):646-653. PubMed ID: 32231245 [TBL] [Abstract][Full Text] [Related]
17. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients. Saemundsson A; Xu LD; Meisgen F; Cao R; Ahlgren G Prostate; 2023 Sep; 83(12):1133-1140. PubMed ID: 36988135 [TBL] [Abstract][Full Text] [Related]
18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
19. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. Den RB; Yousefi K; Trabulsi EJ; Abdollah F; Choeurng V; Feng FY; Dicker AP; Lallas CD; Gomella LG; Davicioni E; Karnes RJ J Clin Oncol; 2015 Mar; 33(8):944-51. PubMed ID: 25667284 [TBL] [Abstract][Full Text] [Related]
20. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Albersen M; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Van Der Poel H; Walz J; De Meerleer G; Bossi A; Haustermans K; Van Poppel H; Spahn M; Joniau S; Eur Urol Focus; 2018 Apr; 4(3):369-375. PubMed ID: 28753838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]